Upload
herbert-paschall
View
221
Download
2
Embed Size (px)
Citation preview
HIV Transplant Investigators Meeting:Introduction and Welcome
HIV Transplant Investigators Meeting:Introduction and Welcome
Nancy Bridges, NIH
Peter Stock, UCSF
Michelle Roland, UCSF
8:00 – 8:10
Meeting ObjectivesMeeting Objectives
8:10 – 8:20
Michelle Roland
1) Administrative Issues
2) Protocol Review
3) Policy
4) Other
Objectives: Administrative IssuesObjectives: Administrative Issues
1) U01 and “Terms and Conditions of Award”
2) Subcontracts: IRB and regulatory issues
3) Site visits pre-start up
4) Steering and Operations Committee; Publications and Presentations Subcommittee
5) Data Management
6) Adverse Events Reporting
Objectives: Protocol IssuesObjectives: Protocol Issues
1) Study Aims
2) Inclusion and Exclusion Criteria
3) Schedule of Events and “Sub-Study Clusters”
4) Medication Regimens and Drug Interactions• Immunosuppressants, ARVs, and
Prophylaxis
5) Clinical Issues• HCV, HBV, and Rejection
6) Stopping Rules
Meeting Objectives: Policy and Other Issues
Meeting Objectives: Policy and Other Issues
1) Publications and Media Policy
2) Reimbursement
3) Donor Consent
4) Complete Good Clinical Practices (GCP) Training
5) Resources on the EMMES Study Website
6) Community Advisory Board
7) Coordinator Meeting Tomorrow• More GPC training• Data entry• Specimen shipping and tracking• Anal HPV swabs and follow-up (UCSF, U Maryland, Mt. Sinai liver, Columbia,
Cedars-Sinai)
Budget and Regulatory IssuesBudget and Regulatory Issues
8:20 – 8:30
Michelle Roland
1) IRB Approvals
2) Regulatory Documents to NIH
3) Site Visits Pre-Start Up
4) Subcontract Conditions (“Milestones”)
Subcontract RequirementsSubcontract Requirements
Milestone #1, first 15 Centers will get initial funding IRB Approvals to Natasha Tomilin
Regulatory Documents to Natasha Tomilin
Milestone #2, to renew subcontract, must demonstrate productivity (screening, enrollment and transplantation), data quality and regulatory adherence. These factors will be reviewed approximately every 6 months
from the time of initial funding.
Concerns will be communicated as soon as identified
Good Clinical Practices TrainingGood Clinical Practices Training
8:30 – 10:00
Barbara Pennington
Study AimsStudy Aims
10:15 – 10:25
Peter Stock
1) Primary Aims
2) Secondary Aims
Specific AimsSpecific Aims
2 hypothesis-driven aims Patient survival
Graft survival
4 exploratory aims
Primary Aim 1:
Evaluate the impact of immunosuppression on patient survival
Primary Aim 1:
Evaluate the impact of immunosuppression on patient survival
Hypothesis: Liver and kidney transplant recipients will have survival rates comparable to other patient groups without HIV infection that are currently considered acceptable transplant candidates.
Control Groups
Control Groups
We anticipate, as with older subjects, that transplantation of HIV+ patients is an acceptable but high risk procedure.
We expect survival may be less than that of age matched controls but that results should be similar to those seen in other poor prognosis groups (e.g. diabetics, hospitalized patients, etc).
The >65 year old normative group was selected because it is relatively common (7% of livers) and represents many organ failure causes.
Also: age-race-donor source-matched controls from
the national registry.
The effect of transplantation on mortality will be
examined by comparing the mortality rate of
subjects awaiting transplant to those receiving an
allograft.
Primary Aim 2:
Evaluate the impact of HIV infection and HAART on graft survival
Primary Aim 2:
Evaluate the impact of HIV infection and HAART on graft survival
Hypothesis 1: HIV+ liver and kidney transplant recipients will have graft survival rates comparable to other patient groups without HIV infection that are currently considered acceptable candidates.
Graft survival in HBV/HCV co-infection
Graft survival in HBV/HCV co-infection
Hypothesis 2: HIV+ liver transplant recipients co-infected with hepatitis B or C will have graft survival comparable to other patient groups with the same viral hepatitis infections but without HIV infection that are currently considered acceptable candidates.
Graft survival in HIVANGraft survival in HIVAN
Hypothesis 3: HIV+ kidney transplant recipients with HIV nephropathy (HIVAN) will have recurrence of HIVAN resulting in impaired renal function and graft survival despite the use of HAART.
Secondary Aim 1:
Explore the impact of post-transplant immunosuppression on changes in CD4+ T cell counts and HIV-1 RNA levels.
Secondary Aim 1:
Explore the impact of post-transplant immunosuppression on changes in CD4+ T cell counts and HIV-1 RNA levels.
RationaleRationale
Immunosuppression may accelerate HIV disease progression, resulting in declines in CD4+ T-cell counts, increased rates of infectious and neoplastic opportunistic complications, and HIV-1 RNA breakthrough on HAART. Such acceleration may be mediated through viral and/or host immunologic pathways.
Alternatively, immunosuppression may result in depletion of HIV-1 reservoirs or reductions in viral rebound and improved HIV-related outcomes.
Secondary Aim 2:
Explore the impact of post-transplant immunosuppression on the host-response to viral co-pathogens, including hepatitis B and C, the human herpesviruses (CMV, EBV, HHV-6, HHV-8) and HPV.
Secondary Aim 2:
Explore the impact of post-transplant immunosuppression on the host-response to viral co-pathogens, including hepatitis B and C, the human herpesviruses (CMV, EBV, HHV-6, HHV-8) and HPV.
RationaleRationale
The combination of immunosuppression and HIV could alter viral activation and/or host immune control of viruses that are associated with the development of clinically significant disease post-transplant.
Secondary Aim 3:
Explore the impact of HIV infection on the alloimmune response and rejection rates.
Secondary Aim 3:
Explore the impact of HIV infection on the alloimmune response and rejection rates.
RationaleRationale
HIV+ transplant recipients may have perturbations
of the immune system that influence the immune
response to solid organ allografts that may have
implications for immunosuppression requirements.
Secondary Aim 4:
Explore the pharmacokinetic interactions between immunosuppressive agents and the hepatically metabolized antiretroviral agents.
Secondary Aim 4:
Explore the pharmacokinetic interactions between immunosuppressive agents and the hepatically metabolized antiretroviral agents.
Committees Committees
10:25 – 10:40
Michelle Roland
1) Steering Committee
2) Operations Committee
Steering Committee Key Responsibilities
Steering Committee Key Responsibilities
Approve protocol and any subsequent changes
Approve the design and implementation of all adjunct studies
Facilitate the conduct and monitoring of the main trial and adjunct studies
Interpret study data: safety and endpoint
Oversee reporting of study results
Recommend the addition or removal of sites participating in the study based upon completion of “milestones”
Implementation and PerformanceImplementation and Performance
The main trial and adjunct studies will be implemented with approval of the Steering Committee and the NIAID Program Officer
Sites will be required to accept and implement the protocol and procedures approved by the Steering Committee Q6 month investigator meeting to consider protocol revisions
SC will oversee mechanisms for assessing the performance of each institution, with particular attention to: accrual of adequate numbers of eligible subjects
timely submission and quality of required data
conscientious observance of protocol requirements
Protocol Exemptions/ViolationsProtocol Exemptions/Violations
No exemptions to inclusion/exclusion criteria for enrollment.
Protocol violations should be driven by patient care needs. Minimize as much as possible Report to IRB and NIH Will be reviewed by Steering Committee for possible
protocol modification
Use of investigational agents must be approved by steering committee (MOP)
Current MembersCurrent Members
Peter Stock and Michelle Roland
Don Stablein: Senior Biostatistician
2 Independent investigators: To Be Named
Robert Zackin and Debi Surlas: Community Representatives
2 Daniella Livnat: NIAID Program Officer
Nancy Bridges: DAIT Medical Officer
Larry Fox: DAIDS Medical Officer
1 John Fung and 1, 2 Margaret Ragni University of Pittsburgh
1, 2 Timothy Pruett, University of Virginia 1 Rotate yearly2 Non-voting members
Operations CommitteeOperations Committee Monthly teleconference Review safety reports (AE/SAE) Monitor site performance (accrual, follow-up, and
withdrawal) Review protection of Human Subjects in research Address unanticipated problems Make recommendations concerning the protocol and
study performance to the Steering Committee for approval
Current MembersCurrent Members
Peter Stock and Michelle Roland
Daniella Livnat: NIAID Program Officer
Nancy Bridges: DAIT Medical Officer
Larry Fox: DAIDS Medical Officer
Natasha Tomilin: NIAID Project Manager
Laurie Carlson: UCSF Study Coordinator
Rodney Rogers: UCSF Project Manager
Don Stablein: Senior Biostatistician
Stopping RulesStopping Rules
10:40 - 10:55
Don Stablein
1) Study Design and Control Groups
2) Sample Size
3) Monitoring
Design SummaryDesign Summary
Protocol contains separate single arm evaluations of kidney transplant
liver transplant
Dual Primary Endpoints patient survival
graft survival (death is an event)
Sample SizeSample Size
150 Kidney
125 Liver
3 Year accrual period
Developed using a Sequential Probability Ratio Test with 95% power for the specified hypotheses of 1 year patient survival
Developing the HypothesesDeveloping the Hypotheses
Anticipate patients may not do as well as average, but believe results will be similar to other high risk patients
Choose null using national data for a high risk group- older (>64 year old) patients older patients have co-morbidities
transplants are common
outcome data are available
Choose alternative using common delta (difference) for both endpoints within organ
Null and Alternative HypothesesOne Year Event Rates
Null and Alternative HypothesesOne Year Event Rates
θ0 θ1
1. Monitoring Patient Survival after a kidney transplant 88% 76%
2. Monitoring Graft Survival after a kidney transplant 83% 71%
3. Monitoring Patient Survival after a liver transplant 82% 67%
4. Monitoring Graft Survival after a liver transplant 78% 63%
DSMB MonitoringDSMB Monitoring
Construct upper confidence limit with 1-tailed significance level of .0001 every 6 months.
Recommend stopping if the targeted national value is not within the interval
Operating Characteristics for Stopping Guidelines Using Semi-Annual Confidence Limits with .0001 1- Sided Significance Level.
% of Trials Recommended for Stopping Prior to Completing 3 Year Accrual Period, 2000 replicates per cell
Operating Characteristics for Stopping Guidelines Using Semi-Annual Confidence Limits with .0001 1- Sided Significance Level.
% of Trials Recommended for Stopping Prior to Completing 3 Year Accrual Period, 2000 replicates per cell
Kidney Survival
Kidney Graft Survival
Liver Survival Liver Graft Survival
Targeted 1-Year Rate
.88 .83 .82 .78
True 1-Year Rate .85 0.1 0 0 0 .80 1.4 0 0 0 .75 16.1 1.6 0.5 0 .70 56.8 16.4 6.2 1.1 .65 89.5 51.4 29.5 8.7 .60 98.5 84.7 63.7 32.9 .55 99.9 97.6 89.4 66.7 Mean 1-Year Estimate For Terminated Studies
0.596
0.561
0.535
0.504
Other Safety MonitoringOther Safety Monitoring
Serious Adverse Events: daily to co-PIs and NIH Medical Officers
HIV Progression Alert Levels: daily report to Operations Committee Viral Load: new onset detectable or >/= 1 log increase
CD4 Count: 25% decline w/o rejection therapy
Other Adverse Events: monthly
Long term graft and patient survival
Inclusion and Exclusion CriteriaInclusion and Exclusion Criteria
10:55 – 11:10
Michelle Roland
1) Inclusion Criteria
2) Exclusion Criteria
3) Narrower Selection Criteria
Key Inclusion CriteriaKey Inclusion Criteria
Age > 1 year old at Pediatric sites UCSF (L/K), University of Chicago (L), Mt. Sinai (K),
Columbia (L) At non-pediatric sites: age >18
CD4+ T-cell count for past 6 months Kidney >/= 200 Liver >/=100 OR >/= 200 if there is a history of protocol
allowed opportunistic complication Use of IL-2 or GM-CSF in the prior six months to increase
CD4 counts is an exclusion
Viral Load Must Be Undetectable for Subjects on ARV Therapy
Viral Load Must Be Undetectable for Subjects on ARV Therapy
< 50 with Amplicor Monitor Ultrasensitive PCR or
< 75 with bDNA Versant version 3.0
If other assays are used, co-PI will define cut-off
Intermittent elevations to 1000 copies/mL, if not persistent on more than 2 sequential measures and followed by undetectable levels, are permitted
Liver Subjects Who AreUnable to Tolerate ARV Therapy
Liver Subjects Who AreUnable to Tolerate ARV Therapy
May have detectable viral load if the study HIV clinician confidently predicts HIV suppression post-transplant Based on ARV history, viral load while on ARVs, adherence,
and available resistance tests
If there is significant doubt about the ability to suppress viral replication post-transplant, the patient should not be enrolled
ARV UseARV Use
Kidney patients and liver patients currently using antiretrovirals must be on stable ARV regimen for at least 3 months prior to entry
OR
Be able to maintain a persistently (always) undetectable HIV-1 RNA level without ARVs This criteria accounts for the very rare long-term non-progressor with no
history of detectable HIV RNA
OI HistoryOI History
Per site policy, a history of the following opportunistic infections or neoplasms may be allowed if subjects have received “appropriate acute and maintenance therapy and have no evidence of active disease.”
Medical record documentation should be provided by the primary medical provider whenever possible.
Specific OI Requirements for EnrollmentSpecific OI Requirements for Enrollment
Cryptococcal meningitis Requires negative serum CRAG
Cytomegalovirus retinitis (“CMV”) No active disease on optho exam. Presence of an
intraocular implant does not imply active disease.
Histoplasmosis Must be on or restart secondary prophylaxis regardless of
CD4 count. (Will be modified if the USPHS/IDSA Guidelines re discontinuation of secondary OI prophylaxis change.)
Specific OI Requirements for EnrollmentSpecific OI Requirements for Enrollment CNS Toxoplasmosis (“Toxo”)
MRI without active disease
Kaposi’s Sarcoma (“KS”) Clinical and radiologic evidence of complete remission with
immune reconstitution. No residual cutaneous lesions and negative chest CT scan
HIV Encephalopathy (“HIV Dementia”) Resolved on HAART with marked improvement in mental
status and increased CD4+ T-cell count and no evidence of progression of CNS disease AND are otherwise considered eligible from a functional standpoint.
Mycobacterial InfectionsMycobacterial Infections
Mycobacterium tuberculosis (TB) Completed standard treatment course
Mycobacterium kansasii Completed standard treatment course
Mycobacterium avium complex (MAC) Completion of 12 months of MAC therapy AND negative
MAC blood culture
Key Exclusion Criteria: OIs Key Exclusion Criteria: OIs
Progressive Mulitfocal Leukoencephalopathy (PML) Chronic Cryptosporidiosis (> 1 month duration) Pulmonary Coccidiodomycosis will be treated per local
site policy in HIV negative transplant candidates (generally 5-year disease-free interval).
Exclusion Criteria: NeoplasmsExclusion Criteria: Neoplasms
Lymphoma (Burkitt’s, immunoblastic or CNS) Any other neoplasm except:
cutaneous kaposi’s sarcoma
in situ anogenital carcinoma
adequately treated basal or squamous cell carcinoma of the skin
solid tumors treated with curative therapy and disease free for more than 5 years
hepatocellular carcinoma in liver candidates
HCV Co-Infected Kidney CandidatesHCV Co-Infected Kidney Candidates
Biopsy-documented cirrhosis requires listing for combined liver and kidney transplant.
Exceptions will be made when sequential rather than simultaneous transplant is appropriate, eg: ineligible for liver transplant due to medical contraindications
such as severe cardiopulmonary disease
stable, compensated cirrhosis deemed by the investigator to not necessitate transplant at this time
“Narrower Selection Criteria”“Narrower Selection Criteria”
Final decisions with regard to the application of narrower selection criteria with regard to pre-transplant viral load and history of opportunistic complications are the prerogative of the individual sites. However, individual sites may not enroll patients who are outside the bounds of the inclusion criteria.
Schedule of EventsSchedule of Events
11:10 – 11:25
Michelle Roland
1) Clinical, Radiology, Laboratory (Safety, HIV, Screening Serology)
2) Clusters/Sub-Studies
3) HCV and HBV co-Infected Subjects
Years:Year
0Year
1
Years 2 & 3
every 3 m1
every 6 m2
Years 4 & 5
every 6 m
Weeks: ScreenDay
0Week
12 4 6 8
10
12
16
20
2636
44
52
53-156 157-260
CLINICAL
Documentation of HIV infection X
Informed Consent X
Symptom & Medical Review plus Physical Exam X9 X X X X X X X X X X X X X X X1 X
PPD 3 X X X X2 X
Vaccination Review (Pneumovax, Hepatitis A and B)
X
Cervical PAP4 X
Pregnancy Test X9 X
RADIOLOGY
CXR X
MRI head 5
Clinical and RadiologyClinical and Radiology
Years:Year
0Year
1
Years 2 & 3
every 3 m1
every 6 m2
Years 4 & 5
every 6 m
Weeks: Screen Day 0 Week 1 2 4 6 8 10 12 16 20 26 36 44 52 53-156 157-260
SAFETY LABS
CBC-diff X9 X X X X X X X X X X X X X X X1 X
Renal/Electrolytes X9 X X X X X X X X X X X X X X X1 X
LFTs X9 X X X X X X X X X X X X X X X1 X
Lipase X X X X X X X X X X X X1 X
LDH X X X X X X X X X1 X
Fasting Lipid Panel (Chol, LDL, HDL, TGL) X X X X2 X
Phosphate (PO4)6 X X X X X X X X X X X X X X X X2 X
Urinalysis X X X X Y2 Y5
Immunosuppressant levels X X X X X X X X X X X X X X1 X
Lactate Monitoring (if on HCV therapy) X9 X X X X X X X X X X X X X X X3 X3
LaboratoryLaboratory
Years:Year
0Year
1
Years 2 & 3
every 3 m1
every 6 m2
Years 4 & 5
every 6 m
Weeks: ScreenDay
0Week
12 4 6 8
10
12
16
20
26
36
44
52
53-156 157-260
HIV LABS
CD4+/CD8+ T-cell count X X X X X X X X X X X X1 X
HIV-1 RNA (bDNA or PCR) X X X X X X X X X X X X1 X
RPR/VDRL7 X9 X X X2 X
Toxoplasmosis Quantitative7 X X X X2 X
G6PD X
MAC-Blood (monthly when CD4 <75)
MAC-Sputum (monthly when CD4 <75)
Urine histoplasmosis antigen (If histo history and CD4 < 200)
CSF JC virus (see protocol) X
General Serology
CMV Ab7 X X X X X2 X
HepBSAg7 X X X X X2 X
HepBSAb7 X X X X X2 X
HepB core Ab7 X X X X X2 X
HCV Ab7 X X X X X2 X
EBV Ab7 X X X X X2 X
“Clusters”“Clusters”
An administrative tool to distribute the “burden” of additional lab studies among sites/subjects
Includes the site where the lab is
Loosely geographically located
Balance numbers to address aims
Total blood volumes/storage blood calculated by cluster
“Clusters”“Clusters”
Years: Year 0Year
1
Years 2 & 3
Years 4 & 5
Weeks: ScreenDay
0Week
12 4 6 8 10 12 16 20 26 36 44 52 53-156 157-260
Co-Pathogen CFC (McCune)
Cytokine Flow Cytometry X X X X Y2 Y5
Co-Pathogen CTL (Brander)
Co-Pathogen ELISPOT X X X X Y2 Y5
HHV8 (Martin)
HHV8 Ab X X X X Y2 Y5
HHV8 Viral Load (plasma) X X X X Y2 Y5
HHV8 PBMC Associated Viral Load X X X X Y2 Y5
HHV8 Saliva Viral Load X X X X Y2 Y5
Herpes Viruses (Rinaldo)
TaqMan Viral Load (CMV, HHV6, EBV)
X X X X X X X X X X X Y2 Y5
NASBA (CMV pp67) assay X X X X X X X X X X X Y2 Y5
RT-PCR (5 EBV RNAs) assay X X X X X X X X X X X Y2 Y5
Transplant Immunology (Stock) – UCSF real time, others stored)
MLC X X X X Y2 Y5
Donor tissue or blood X
Cluster 1 Sub-Studies: Co-Pathogen Virology/Immunology; Transplant Immunology
Cluster 1 Sub-Studies: Co-Pathogen Virology/Immunology; Transplant Immunology
Years: Year 0Year
1Years 2 & 3 Years 4 & 5
Weeks:Screen Week
12 4 6 8 10 12 16 20 26 36 44 52 53-156 157-260
Pharmacokinetics (Benet) (UCSF ONLY)
PI/NNRTI/CSA pK X X X X X Y2
Urine toxicology X X X X X Y2
pGP Phenotype X
HPV (Palefsky)
Anal PAP1 X
Specimen Storage
Fresh blood shipped to BBI3 X X X X X Y2 Y5
Cluster 1 Continued: pK and HPV
Years: Year 0Year
1
Years 2 & 3
Years 4 & 5
Weeks: Screen Day 0Week
12 4 6 8 10 12 16 20 26
36
44 5253-156
157-260
Co-Pathogen CFC (McCune)
Cytokine Flow Cytometry X X X X Y2 Y5
Co-Pathogen CTL (Brander)
Co-Pathogen ELISPOT X X X X Y2 Y5
HHV8 (Martin)
HHV8 Ab X X X X Y2 Y5
HHV8 Viral Load (plasma) X X X X Y2 Y5
HHV8 PBMC Associated Viral Load
X X X X Y2 Y5
HHV8 Saliva Viral Load X X X X Y2 Y5
Herpes Viruses (Rinaldo)
TaqMan Viral Load (CMV, HHV6, EBV)
X X X X X X X X X X X Y2 Y5
NASBA (CMV pp67) assay X X X X X X X X X X X Y2 Y5
RT-PCR (5 EBV RNAs) assay X X X X X X X X X X X Y2 Y5
Specimen Storage
Fresh blood shipped to BBI1 X X X X X Y2 Y5
Cluster 2 Sub-Studies: Co-Pathogen Virology/Immunology
Cluster 2 Sub-Studies: Co-Pathogen Virology/Immunology
Years: Year 0Year
1Years 2
& 3Years 4
& 5
Weeks: ScreenDay
0Week
12 4 6 8 10 12 16 20 26 36 44 52 53-156 157-260
HIVAN (Klotman)
Biopsy Tissue1 X
HPV (Palefsky) – liver patients only
Anal PAP X
Specimen Storage
Fresh blood shipped to BBI1 X X X X X Y2 Y5
Cluster 3 Sub-Studies: HIVAN, HPVCluster 3 Sub-Studies: HIVAN, HPV
Years: Year 0Year
1Years 2 & 3
Years 4 & 5
Weeks: ScreenDay
0Week
12 4 6 8 10 12 16 20 26 36 44 52 53-156
157-260
HPV (Palefsky) – Columbia only-
Anal PAP1 X
Specimen Storage
Fresh blood shipped to BBI X X X X X Y2 Y5
Cluster 4 Sub-Studies: HPVCluster 4 Sub-Studies: HPV
HCV + Subjects: Virology and ImmunologyHCV + Subjects: Virology and Immunology
Years: Year 0Year
1Years 2 &
3Years 4 & 5
Weeks: Screen Day 0Week
12 4 6 8 10 12 16 20 26 36 44
52
53-156 157-260
HCV (Oldach)
Biopsy (protocol mandated biopsies)1 X
HCV RNA2 X X X X Y2 Y5
HCV Genotype X
HCV Quasispecies X X X X Y2 Y5
HCV Ab-RIBA X
CTL (Brander)
HCV Elispot X X X X Y2 Y5
CFC (McCune)
Cytokine Flow Cytometry X X X X Y2 Y5
General
Abdominal CT X
1. Liver: biopsy at month 6 post transplant then annually. Kidney: biopsy at month 6, year 2.5, and year 5 if insurance is willing to cover.
2. Liver subjects receiving HCV therapy must have additional HCV RNA at 2, 6 and 12 months post-therapy initiation. Kidney subjects receiving HCV therapy must have additional HCV RNA at 3 and 12 months post-therapy initiation.
HBV + Subjects: VirologyHBV + Subjects: Virology
Years: Year 0Year
1Years 2 & 3 Years 4 & 5
Weeks:Scree
nDay
0Week
12 4 6 8 10 12 16 20 26 36 44 52 53-156 157-260
HBV (Terrault)
Biopsy (NO protocol mandated biopsies) X
HepBSAb X X X X Y2 Y5
HepBSAg X X X X Y2 Y5
HepB DNA X X X X Y2 Y5
Anti HDV X X X X Y2 Y5
Questions and AnswersQuestions and Answers
11:25 – 11:45
ImmunosuppressivesImmunosuppressives
12:30 – 12:45
Peter Stock
1) Calcineurin Inhibitors
2) CellCept
3) Steroids
4) Acute and Chronic Rejection
Calcineurin Inhibitor Calcineurin Inhibitor
Cyclosporine initial dose recommendations• PI-containing regimen: 25 – 50 mg PO BID.
This also applies to combined PI-NNRTI-based regimens• When used with a non-PI containing regimen: 200 – 450
mg PO BID (200 mg if on Nevirapine; 250 – 450 mg if on Efavirenz)
Tacrolimus initial dose recommendations• PI-containing regimen: 1 mg PO once to twice per week.
This also applies to combined PI-NNRTI-based regimens• When used with an non-PI-containing regimen: 1 - 2 mg
bid PO
CellCept (MMF) and SteroidsCellCept (MMF) and Steroids
Standard dosing (1000 mg PO BID) will be initiated in all kidney and liver subjects.
Dosing should be modified based on toxicity (neutropenia, GI) and clinical judgment.
MMF may be tapered in stable liver transplant recipients after 6 months of therapy.
Steroid induction, taper, and maintenance will be according to local site practice.
Notes Notes Induction with an IL-2 receptor inhibitor (anti-CD25
antibody) may be utilized for kidney transplants, but no induction will be used for liver transplants.
Immunosuppressant doses will be modified to obtain routine trough levels standard for kidney and liver transplants.
In the case of HIV disease progression, immunosuppressive doses may be reduced to prevent clinical decline.
Notes Notes The transplant team/study coordinator must be notified
of any change in immunosuppressive dosing because there may be interactions with antiretroviral drug dosing and visa versa.
Other agents to be used tx of acute and chronic rejection Sirolimus
Anti-lymphocyte preparations (Thymoglobulin)
Antiretrovirals and ResistanceAntiretrovirals and Resistance
12:45 – 1:00
Michelle Roland
1) General Management Principals
2) Responding to New Detectable Viral Load
3) Resistance Testing
Avoiding the Development of ARV Resistance
Avoiding the Development of ARV Resistance
Effective viral suppression requires multiple ARVs
Viral resistance develops when the ARV regimen is not potent enough Inadequate number of different drugs
Inadequate dose of drug
Inadequate dosing schedule (eg missed doses)
ARVs should be discontinued and restarted in entire combinations, not parts of combinations
Resistance DevelopmentResistance Development
HIV drug resistance can develop very quickly, within days, for some drugs Lamivudine (lamivudine) and all the NNRTIs (efavirenz,
nevirapine)
Cross resistance is a problem with all these drugs
In the post-op period, it is best to hold all ARVs until the patient is able to take po’s, there is no vomiting, and there are no tests anticipated that will require an NPO period.
Managing HBV and HIV TherapyManaging HBV and HIV Therapy
In most cases, unless HIV drug resistance is already present, HBV therapy should only be initiated in combination with the full HIV ARV combination (except HBIg)
This can be particularly complicated with pre-transplant management in a patient with bad liver disease in whom you want to avoid hepatotoxins.
New Detectable HIV Viral LoadNew Detectable HIV Viral Load
May be true failure to control HIV replication and harbinger of “breakthrough”
May be a “blip”
May be a false positive
Recommend repeat ASAP so if it is a true and persistent positive, the pros and cons of modifying ARV therapy to minimize resistance development can be considered
Resistance TestingResistance Testing
HIV Physician will determine when to request in both screening and follow-up period
2 types are available: genotypic and phenotypic
Main limitation is sensitivity Can only detect minority quasispecies > 20% of population
Drug selection pressure drives proportion of quasispecies that will be resistant versus wild type
Reversion to wild type does not mean resistant virus is cleared
Can use to rule drugs out, but not to rule them in
Second significant limitation is interpretation of sequence/phenotype
ProphylaxisProphylaxis
1:00 – 1:15
Michelle Roland
1) Transplant-Specific
2) HIV-Specific
3) Special Issues in Subjects with an OI History (Recommendations from the MOP)
Primary ProphylaxisPrimary Prophylaxis
Subject with no history of the disease
At risk due to defined CD4 reduction or transplantation
Standard prophylaxis recommendations
Usually one drug
Often discontinued when CD4 count is high enough unless there is transplant associated risk (eg PCP)
Secondary Prophylaxis = Chronic Maintenance Therapy
Secondary Prophylaxis = Chronic Maintenance Therapy
Subjects with a history of the disease
Secondary prophylaxis should be reinstituted:
post- transplant for 1 month
during treatment of acute rejection and for 1 month following completion of rejection therapy
if CD4 cell count drops below the defined level
Secondary prophylaxis should be discontinued when CD4+ T-cell count is above the defined level for six months
unless the patient is within one month of completion of therapy for a rejection episode
These are often more intensive regimens than primary prophylaxis regimens (eg usually 2 drugs).
Pneumocystis Carinii Pneumonia (PCP)Pneumocystis Carinii Pneumonia (PCP)
Primary and Secondary Prophylaxis are indicated in all patients for life and should start immediately post-transplant.
Preferred Regimen: TMP-SMX DS or SS daily
Alternatives: TMP-SMX DS TIW, dapsone QD (contraindicated if G6PD deficient), atovaquone QD or aerosolized pentamidine monthly
CMV Primary ProphylaxisCMV Primary Prophylaxis
Per Site Practice
CMV Secondary ProphylaxisCMV Secondary Prophylaxis
CD4 cut-off: ≤ 100 to start and >/= 200 x 6 months to discontinue.
Preferred: valcyte QD
Alternative: oral ganciclovir TID
MAC Primary ProphylaxisMAC Primary Prophylaxis
CD4+ T-cell count ≤ 75 to start and >/= 100 x 6 months to discontinue.
Preferred: Azithromycin weekly
Alternatives: clarithromycin BID (drug interactions with immunosuppressive agents must be considered). Because of the risk of rejection due to drug interaction with calcinerin inhibitors, rifabutin and rifampin should be avoided for prophylaxis unless all other alternatives have been exhausted.
MAC Secondary ProphylaxisMAC Secondary Prophylaxis
CD4 cut-off: ≤ 75 to start and >/= 100 x 6 months to discontinue.
Preferred: azithromycin QD plus ethambutol QD plus leucovorin QD.
Alternatives: replace azithromycin with clarithromycin BID (drug interactions with immunosuppressive agents must be considered). Because of the risk of rejection due to drug interaction with calcinerin inhibitors, rifabutin and rifampin should be avoided for prophylaxis unless all other alternatives have been exhausted.
Toxoplasmosis Primary ProphylaxisToxoplasmosis Primary Prophylaxis
Toxo IgG-positive subjects with CD4+ T-cell count ≤ 200.
Preferred: DS TMP-SMX QD
Alternatives: SS TMP-SMX QD or atovaquone. If on dapsone for PCP need to add + pyrimethamine QD + leucovorin QD
Toxoplasmosis Secondary ProphylaxisToxoplasmosis Secondary Prophylaxis
CD4 cut-off: </= 200 to start; > 200 for 6 months to discontinue
Preferred: pyrimethamine QD plus sulfadiazine QD plus leucovorin QD.
• Separate PCP prophylaxis should be discontinued if this regimen is used.
Alternative: for patients who cannot tolerate sulfa drugs pyrimethamine QD plus clindamycin QID.
• PCP prophylaxis must be continued with this regimen.
Cryptococosis Primary ProphylaxisCryptococosis Primary Prophylaxis
None Recommended
Cryptococcosis Secondary ProphylaxisCryptococcosis Secondary Prophylaxis
CD4 cut-off: </= 200 to start; > 200 for 6 months to discontinue
Preferred: fluconazole qD (200 mg)
Severe toxicity from calcineurin inhibitors may result if daily fluconazole (or another azole) is used
The dose of calcineurin inhibitors should be reduced by 50%; sometimes more significant dose reduction is required.
Daily calcineurin inhibitor trough levels should be monitored during the first week of therapy, or longer if necessary.
Similar adjustments are required in the dosing of sirolimus and tacrolimus.
Histoplasmosis Primary ProphylaxisHistoplasmosis Primary Prophylaxis
None Recommended
Histoplasmosis Secondary ProphylaxisHistoplasmosis Secondary Prophylaxis
Prophylaxis must be continued regardless of CD4 count until DHHS guidelines are modified to recommend a safe level for discontinuation
Preferred: itraconazole DD Alternatives: high dose fluconazole (400 mg)
QD
Severe toxicity from calcineurin inhibitors may result if daily azoles are used
CandidiasisCandidiasis
Per site practice, but fluconazole 100mg once per week for 3 months, supplemented with Mycelex troches, is highly recommended.
Severe toxicity from calcineurin inhibitors may result if daily fluconazole (or another azole) is used
See previous recommendations for dose
adjustments
EBV ProphylaxisEBV Prophylaxis
Indicated for EBV negative recipient with positive donor.
Regimen: IV ganciclovir QD while hospitalized then, ganciclovir PO TID x 1 year. • Patients should not be continued on acyclovir
if they are on ganciclovir.
Anticipated Drug Interactions/DosingAnticipated Drug Interactions/Dosing
1:15 – 1:30
Laurie Carlson
1) Protease Inhibitors and Calcineurin Inhibitors
2) NNRTIs
Dosing of Protease Inhibitors with Calcineurin Inhibitors
Dosing of Protease Inhibitors with Calcineurin Inhibitors
Drug/ Protease Inhibitors Initial dose of CSA Maintenance dose of CSA CsA trough
Kaletra 25 mg bid or qd 25 mg qd or qod ?
Nelfinavir 50-75 mg bid 25 mg bid Avg 112 R 59-174
Indinavir 75-100 mg bid 75 bid (limited data) Avg 125; R 74-175
Nelfinavir/Amprenavir 50 mg bid 25 mg in am and 50 mg in pm Avg 103 R 95-109
Drug/ Protease Inhibitors Initial dose of Prograf Maintenance dose Prograf FK trough
Kaletra .5 mg bid .5 mg qod ?
Nelfinavir 1 mg bid .5 mg qd to .5 mg qod 3.6
Indinavir ND ND
Dosing of NNRTIs with Calcineurin Inhibitors
Dosing of NNRTIs with Calcineurin Inhibitors
Drug/ NNRTI Initial dose of CSA Maintenance dose of CSA CsA trough
Nevirapine 200-250 mg bid 100-175 mg bid Avg 122; R 45-195
Sustiva 350 -450 mg bid 250-400 mg bid Avg 117, R84-182
Drug/ NNRTI Initial dose of Prograf Maintenance dose Prograf FK trough
Nevirapine 3 mg bid 1.0-2 mg bid Avg 6; R 3.1-9.8
Sustiva ND ND
Dosing of PI & NNRTIs Combinations with Calcineurin Inhibitors
Dosing of PI & NNRTIs Combinations with Calcineurin Inhibitors
NNRTI/PI combo Initial dose of Prograf Maintenance dose Prograf FK trough
Sustiva/ Amprenavir 1 mg bid 1.0 q am and .5 qpm Avg 9.6; R 6.3-10.6
Nelfinavir/Nevirapine .5 bid .5 mg qd- qod Avg 6; R 2-12
NNRTI/PI combo Initial dose of CSA Maintenance dose CSA CsA trough
Sustiva/ Amprenavir 100 mg bid ND 114-182
Nelfinavir/Nevirapine 25mg bid 25 mg qd -bid Avg 169 R 152-176
Indinavir/Nevirapine 150 mg bid 100 mg bid Avg 139 R 85-173
Kaletra/Nevirapine 25 bid 25 qd-qod R 45-254; avg 129
Dosing of Antiretrovirals with Sirolimus Dosing of Antiretrovirals with Sirolimus
ARV CI Maintenance dose of Sirolimus SRL trough
Nelfinavir Neoral 25 mg bid 1mg BIW Nelfinavir/Sustiva Neoral 25 mg bid 1 mg BIW Kaletra/Nevirapine Neoral 25 qod 1 mg q week Kaletra None 1 mg BIW 1.9 Nelfinavir None 1 mg qod 3.9
Factors Influencing DosingFactors Influencing Dosing
Graft function
Initiation of ARV therapy post transplant
Tenofovir and renal insufficiency
Side effects
Education
Questions and AnswersQuestions and Answers
1:30 – 1:45
HCV Co-Infected PatientsHCV Co-Infected Patients
2:00 – 2:20
Peter Stock
1) Liver Patients
2) Kidney Patients
Treatment of HCV + Liver Recipients: When?
Treatment of HCV + Liver Recipients: When?
HCV treatment will not be initiated preemptively post-transplant No data to suggest that HCV RNA clearance rates are higher Minimize drug interactions and toxicity in the early post-transplant period
HCV treatment will be initiated if biopsy shows severe or progressive recurrent HCV disease
HAI score> 8 and/or fibrosis stage >2 are considered indications for treatment by most transplant physicians but the decision to treat will ultimately be determined by the treating physician.
Biopsies in HCV + Liver Recipients: When to Do? Who Reads?
Biopsies in HCV + Liver Recipients: When to Do? Who Reads?
Protocol biopsies: 6 and 12 months post transplant, then annually
And at any time as clinically indicated
Treatment decisions based upon local pathologist reading
For outcomes determinations, biopsies will be read by a central pathologist and will be scored using the Ishak version of Knodell
HCV Treatment RegimenHCV Treatment Regimen
Peg-INF or standard INF plus ribavirin. Not altered based upon prior INF experience or genotype.
Peg-INF a-2b 1.0-1.5 ug/kg or Peg-INF a-2a 180 ug weekly Start at half dose Increase to full-dose in 2 weeks if blood counts are acceptable
Ribavirin 200 mg PO BID x 2 weeks, then 400 mg PO BID x 2 weeks if tolerated, then 10-13 mg-kg as divided dose if tolerated. Transplant patients have renal clearance issues that make increasing
ribavirin dose too high and/or too quickly result in drug-limiting anemia. Thus, ribavirin should be titrated up slowly as tolerated.
Monitoring on HCV TreatmentMonitoring on HCV Treatment
Pre-therapy: CBC, liver, renal, TSH, lipids, CXR, EKG Months 1-2 post-therapy initiation: weekly CBC Months 3, 6, 9, 12 post-therapy initiation: TSH HCV RNA: all HCV co-infected patients have baseline, month 3,
6, 12 and years 2 and 5. Subjects receiving HCV therapy have additional HCV RNA at 2, 6 and
12 months post-therapy initiation.
Depression screen monthly for first 3 months, then every 3 months.
Patients should be provided with 24-hour clinical contact number for adverse effect notification.
Length of TreatmentLength of Treatment 12 month minimum. At 12 months, response will be determined
by measurement of HCV RNA (if quantitative negative, will do qualitative), AST/ALT and liver histology.
Types of Response and Actions: HCV RNA negative at 6 and 12 months: stop treatment HCV RNA positive but liver histology improved: stop treatment.
Consider re-initiation of therapy if disease activity (histology, biochemical) increases.
HCV RNA positive but liver histology unchanged or worse: Continue treatment for another 12 months (or consider for experimental therapies).
Marrow-Supportive Therapy Marrow-Supportive Therapy
Erythropoietin Start when hemoglobin is <10g/dl. Dose: 40,000 IU subcutaneously weekly. If hemoglobin decreases below 8.0 g/dL, discontinue
ribavirin until >10 g/dL (women) or >12 g/dL (males) on erythropoietin. If ribavirin is restarted, use 50% of the dose used when ribavirin was discontinued.
G-CSF Start when ANC is <1,000/mm3. Dose: 300 ug twice weekly. If subsequent trough ANC
>3000/mm3, reduce dose to 150 ug twice weekly or 300 ug once weekly. Continued until the end of treatment.
Pre-Transplant Treatment of HCV + Kidney Candidates: When?
Pre-Transplant Treatment of HCV + Kidney Candidates: When?
Pre-transplant therapy with interferon/peg-interferon will be considered in each patient but is not required.
Pre-transplant therapy is strongly recommended if: Biopsy shows stage stage 2 or greater disease All patients with non-1 genotypes, regardless of
stage of disease, since the viral clearance rates with INF treatment are >50% for this subgroup.
Post-Transplant Treatment of HCV + Kidney Recipients: When?
Post-Transplant Treatment of HCV + Kidney Recipients: When?
Advanced or progressive liver disease post-transplant will be targeted for anti-HCV treatment
Post-transplantation therapy will be offered but not required in the following circumstances: Biopsy evidence of progressive disease (increase in fibrosis
score) Any biopsy showing stage 3 or 4 disease Biopsy and clinical features of fibrosing cholestatic hepatitis
Biopsies in HCV + Kidney Recipients: When to Do? Who Reads?
Biopsies in HCV + Kidney Recipients: When to Do? Who Reads?
Pre-transplant: assess histological stage; rule out cirrhosis Protocol biopsies: month 6, year 2.5, and year 5 (use GCRC) At any time for clinical indications:
AST or ALT >2 ULN for >/= 3 months
significant change in AST, ALT, alkaline phosphatase or total bilirubin from baseline in order to rule out concurrent conditions (e.g. drug toxicity, biliary disease, fibrosing cholestatic hepatitis or other progressive HCV disease).
Treatment decisions based upon local pathologist reading For outcomes determinations, biopsies will be read by a central
pathologist and will be scored using the Ishak version of Knodell
HCV Treatment RegimenHCV Treatment Regimen
Pre-transplant: Peg- INF or standard INF not altered based upon prior INF experience
standard INF 3 million units three times weekly
pegylated INF 1.0-1.5 ug/kg (peg-INF alfa-2b) weekly or 180 ug weekly (peg-INF alfa-2a).
Post-transplant: Peg-INF or standard INF plus ribavirin.
Monitoring on HCV TreatmentMonitoring on HCV Treatment
Same as in liver recipients
Length of HCV Treatment:Pre-Transplant
Length of HCV Treatment:Pre-Transplant
Minimum of 3 months At 3 months, if a 2-log reduction in HCV RNA or HCV RNA
negative, continued for a total of 6 to 12 months (depending upon genotype and stage of fibrosis). If the patient does not achieve at least a 2-log reduction in HCV RNA by
month 3 of treatment, the treatment will be discontinued.
Note: liver and combined kidney-liver candidates
will not be encouraged to treat HCV pre-transplant (as kidney candidates are) as it is assumed that they have already
exhausted all medical therapy options for the treatment of HCV.
Length of Treatment Post-TransplantLength of Treatment Post-Transplant 12 months. HCV RNA at 3 and 12 months post-therapy (if quantitative negative at 12 months, will do qualitative Repeat biopsy following 12 months of treatment recommended
Types of Response and Actions: HCV RNA negative at end of treatment: stop and observe for relapse. HCV RNA positive at end of treatment: stop and observe for histological progression. Consider re-initiation of therapy if histological activity or fibrosis score increases.
Marrow-Supportive TherapyMarrow-Supportive Therapy
EPO and G-CSF as for liver recipients
HBV Co-Infected PatientsHBV Co-Infected Patients
2:20 – 2:30
Peter Stock
1) Liver Patients
2) Kidney Patients
Biopsies: Liver and Kidney RecipientsBiopsies: Liver and Kidney Recipients
No protocol-mandated biopsies
Biopsies should be obtained if: AST or ALT > 1.5 ULN Any HBV virological breakthrough Suspicion of drug hepatotoxicity
Treatment Guidelines for Liver and Kidney Candidates: Pre-Transplant
Treatment Guidelines for Liver and Kidney Candidates: Pre-Transplant
If lamivudine naïve, treat with lamivudine 150mg BID May use lamivudine plus adefovir or tenofovir
If lamivudine resistant, use tenofovir or adefovir plus lamivudine
(Emtriva [FTC] has not been added to protocol yet)
Treatment Guidelines for Liver and Kidney Recipients: Peri-Transplant
Treatment Guidelines for Liver and Kidney Recipients: Peri-Transplant
Continue lamivudine, adefovir or tenofovir as prescribed pre-transplant Adjust for renal function If unable to start HIV antiretroviral therapy post-
transplant, hold HBV antiviral medication until able to start HIV antiretroviral therapy
Treatment Guidelines for Liver Recipients: Peri-Transplant
Treatment Guidelines for Liver Recipients: Peri-Transplant
HBIg Dosing Schedule: 10,000 IU during the anhepatic phase and on admission to ICU. 5,000 IU Q6 hours for days 1 and 2 post-op, and 10,000 IU daily for days 3 – 7 post-op. Check HBsAg on day 2 and if positive, give 10,000 IU every 12 hours until HbsAg negative.
If patient is HBV DNA detectable pre liver transplant, closer monitoring of HBIG dosing is advised, especially if HBV antivirals are on hold.
If HBV antivirals are held, check HbsAg daily and continue 5000 IU Q6 hours until HbsAg is negative, then 10,000 IU daily for 7 days of treatment.
HBV Treatment Guidelines for Liver Recipients: Post-Transplant
HBV Treatment Guidelines for Liver Recipients: Post-Transplant
Continue HBV and HIV antiretrovirals indefinitely
HBIG 10,000 IU monthly for 3 months, then 5,000 IU for next 3 months, then 2,500 IU (IM or IV) monthly thereafter, indefinitely
Monitor HBsbAg and anti-HBs titer monthly.
Monitor HBV DNA levels as clinically indicated (AST or ALT > 1.5 ULN) and every 3 months.
Treatment Guidelinesfor Kidney Recipients: Post-Transplant
Treatment Guidelinesfor Kidney Recipients: Post-Transplant
If patient has stage 3 or 4 fibrosis, antiviral therapy should be continued indefinitely
For patients with </= stage 2 fibrosis, antiviral therapy can be stopped after 12 months if the following criteria are met:
Normal liver enzymes
Minimal (5 mg QD or QOD) or no prednisone
No recent change in immunosuppression (stable for preceding 3 months)
Treatment Guidelinesfor Kidney Recipients:
Restarting HBV Therapy
Treatment Guidelinesfor Kidney Recipients:
Restarting HBV Therapy Restart HBV therapy and continue indefinitely if AST or ALT
increase to > 1.5 ULN and HBV DNA > 105 copies/mL after treatment is stopped.
Additionally, give HBV antiviral therapy whenever a patient receives treatment for rejection; continue for at least 4 months; stop only when:
Normal liver enzymes
Minimal (5 mg QD or QOD) or no prednisone
No recent change in IMS (stable for preceding 3 months)
Monitoring Guidelines: Liver and Kidney Recipients
Monitoring Guidelines: Liver and Kidney Recipients
Pre-transplant : HBV DNA every 3 months
Peri-transplant : HBV DNA immediately pre-transplant.
Post-transplant : In addition to the protocol-mandated labs, it is recommended for clinical management that HBV DNA be followed every 3 months and as clinically indicated (AST or ALT > 1.5 ULN) and that HBSAg and HBSAb be followed monthly
RejectionRejection
2:30 – 2:45
Peter Stock
1) Management
2) Definitions
Acute and Chronic RejectionAcute and Chronic Rejection A biopsy will be performed in all cases of suspected rejection
Therapy may be initiated </= one day prior to the results of the biopsy if clinically indicated.
Treatment for > 1 day, including increases in the dose of immunosuppressive medications, cannot be sustained without a biopsy, unless the managing physicians believe biopsy is unsafe.
Treatment of rejection episodes will be according to local site practices and may include sirolimus.
OKT3 and polyclonal anti-lymphocyte preparations have resulted in prolonged reduction in CD4+ counts in HIV infected transplant recipients, and their use should be restricted to treatment for severe rejection.
Definition of RejectionDefinition of Rejection
Kidney (NIH CCTT Definition) Type I: mononuclear infiltrate in > or =5% of cortex, a total of at least
three tubules with tubulitis in 10 consecutive high-power fields from the most severely affected areas, and at least two of the three following features: edema, activated lymphocytes, or tubular injury.
Type II: arterial, or arteriolar, endothelialitis with or without the preceding features.
Type III: arterial fibrinoid necrosis or transmural inflammation with or without thrombosis, parenchymal necrosis, or hemorrhage.
Liver (Banff Criteria) Liver rejection will be defined by the Banff global grading scheme and
Banff rejection activity index.
Questions and AnswersQuestions and Answers
2:45 – 3:10
Adverse Event ReportingAdverse Event Reporting
3:10 – 3:25
Natasha Tomlin
1) TBD
Data ManagementData Management
3:25 – 3:45
Craig Lazar
1) TBD
Website ModificationsWebsite Modifications
Updated sample letter requesting reimbursement
Updated PDFs for relevant studies
Updated contact list of experienced folks willing to help
Publication and Media PolicyPublication and Media Policy
3:45 – 3:55
Michelle Roland
1. Membership
2. Roles
PPSC MembershipPPSC Membership
1 from each Clinical Site Balance transplant and HIV
PI discuss with key personnel and elect
1 from each Lab Site
1 from CAB
Add expertise as needed for concepts
PPSC elects it’s chair
PPSC RolesPPSC Roles
Specific roles and procedures to be determined by PPSC
Guiding principles:
“Old Ideas” “New Ideas”
Multi-Site Study Aim PI Concept Sheet (encouraged)
Single Site Concept Sheet None Required(discouraged) (requested)
Reimbursement ConsiderationsReimbursement Considerations
3:55 – 4:10
Peter Stock, Cheryl Janov
Who Paid in Pilot Multi-Site Study?Who Paid in Pilot Multi-Site Study?
• Kidney recipients:• 69% Medicare
• 8% Medicaid
• 23% Private Insurers
• Liver recipients: • 10% Medicare
• 20% Medicaid
• 40% Private Insurers
• 30% CA Research Funds
WebsiteWebsite
Sample letters to insurers
Supporting articles to include with coverage request
IRB Re: ExperimentalIRB Re: Experimental
The procedure is not experimental
The population/context is
Donor ConsentDonor Consent
Required at each site
Must include disclosure of candidate HIV status prior to invasive procedures in donor
Alternatives: cadaver donor, off-study transplant
Community Advisory BoardCommunity Advisory Board
4:10 – 4:20
Michelle Roland, Debi Surlas and Robert Zackin
1) TBD
Closing DiscussionClosing Discussion
4:20 – 5:00
“Parking Lot” Issues from SC“Parking Lot” Issues from SC
Pre-eligible consent/enrollment for outcomes
Specimen request review process